Matches in Wikidata for { <http://www.wikidata.org/entity/Q65358053> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q65358053 description "clinical trial" @default.
- Q65358053 description "ensayu clínicu" @default.
- Q65358053 description "klinisch onderzoek" @default.
- Q65358053 description "клінічне випробування" @default.
- Q65358053 name "Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors" @default.
- Q65358053 name "Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors" @default.
- Q65358053 type Item @default.
- Q65358053 label "Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors" @default.
- Q65358053 label "Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors" @default.
- Q65358053 prefLabel "Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors" @default.
- Q65358053 prefLabel "Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors" @default.
- Q65358053 P1050 Q65358053-BF01BD22-535B-42AC-AA06-5734CECFB3DF @default.
- Q65358053 P1132 Q65358053-5CFA2429-A4EF-49A0-8D82-B1BC408DF2C9 @default.
- Q65358053 P1476 Q65358053-5E038D8D-A52F-4852-BCEB-FE5426C4E38F @default.
- Q65358053 P17 Q65358053-50589A4D-1907-439A-B5D3-0C14B0AA1CDD @default.
- Q65358053 P1813 Q65358053-3326DAE0-BAB3-4832-8E33-4576F99FAB83 @default.
- Q65358053 P3098 Q65358053-DBEB76FD-3C88-484E-B596-FD2B625B7CB4 @default.
- Q65358053 P31 Q65358053-1E8399E4-0EBA-443A-A938-2FE7830412AC @default.
- Q65358053 P4135 Q65358053-51D23D24-C099-40BB-875D-1BCA7CAE9380 @default.
- Q65358053 P4844 Q65358053-6E0E7608-6161-40C6-B846-082C9ABB9F3D @default.
- Q65358053 P4844 Q65358053-7300DAE5-899B-4380-B707-64748995E3BD @default.
- Q65358053 P4844 Q65358053-DE879FAB-04FA-44AE-9964-29CAF4FE7244 @default.
- Q65358053 P4844 Q65358053-F187CA8A-9B2B-4A95-BD18-4693EAE399E0 @default.
- Q65358053 P580 Q65358053-7F8F8495-4ED1-4886-856A-3338DD787D52 @default.
- Q65358053 P582 Q65358053-8B437836-6D8C-4548-918B-F0647401F6A5 @default.
- Q65358053 P6099 Q65358053-DD1200D9-4293-4396-870A-772A0C606959 @default.
- Q65358053 P6153 Q65358053-53C384AA-39BD-4BF8-82CB-D3FE80595AEC @default.
- Q65358053 P6153 Q65358053-666F1A9C-255C-423A-9645-391B55DB22D5 @default.
- Q65358053 P6153 Q65358053-6E9A7699-0C39-4CAD-8CAB-CA799B266303 @default.
- Q65358053 P6153 Q65358053-72F885A3-5EEB-4A71-85E1-22B3137CE44D @default.
- Q65358053 P6153 Q65358053-8F19F655-1925-49CF-B7A9-E7F9E3965342 @default.
- Q65358053 P6153 Q65358053-9489F97D-7DCA-48A8-B8BD-06E68ACF540B @default.
- Q65358053 P8363 Q65358053-19547FF6-7A4E-4666-9716-25DC1E9A9C4D @default.
- Q65358053 P1050 Q200741 @default.
- Q65358053 P1132 "+180" @default.
- Q65358053 P1476 "Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT" @default.
- Q65358053 P17 Q30 @default.
- Q65358053 P1813 "SJATRT" @default.
- Q65358053 P3098 "NCT02114229" @default.
- Q65358053 P31 Q30612 @default.
- Q65358053 P4135 "+21" @default.
- Q65358053 P4844 Q27260984 @default.
- Q65358053 P4844 Q408524 @default.
- Q65358053 P4844 Q412415 @default.
- Q65358053 P4844 Q415588 @default.
- Q65358053 P580 "2014-05-14T00:00:00Z" @default.
- Q65358053 P582 "2023-05-01T00:00:00Z" @default.
- Q65358053 P6099 Q42824440 @default.
- Q65358053 P6153 Q1164246 @default.
- Q65358053 P6153 Q1468161 @default.
- Q65358053 P6153 Q23074176 @default.
- Q65358053 P6153 Q50497514 @default.
- Q65358053 P6153 Q5098193 @default.
- Q65358053 P6153 Q622664 @default.
- Q65358053 P8363 Q78089383 @default.